NDAINTRAVENOUS, SUBCUTANEOUSPOWDERPriority Review
Approved
May 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
VIDAZA (azacitidine) by Bristol Myers Squibb is nucleic acid synthesis inhibitors [moa]. Approved for acute myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia. First approved in 2004.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIDAZA (azacitidine) is a nucleoside metabolic inhibitor that works by inhibiting nucleic acid synthesis to treat hematologic malignancies and select solid tumors. It is approved for acute myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, and multiple other blood and solid cancers. The drug is administered intravenously or subcutaneously as a powder formulation.
$49KPart D
LOE Approaching3.0 years to LOEVIDAZA faces patent expiration in ~3 years with minimal current spending, signaling a contracting commercial footprint and likely reduced team staffing.
Mechanism of Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Class:
Nucleoside Metabolic Inhibitor
Indications (3)
Worked on VIDAZA at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.